Determine Feasibility of Quantifying Apoptosis and Bcl-2 Expression in CTCs in Women With Metastatic Breast Cancer
Status: | Active, not recruiting |
---|---|
Conditions: | Breast Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 6/4/2016 |
Start Date: | April 2005 |
A Pilot Study to Determine the Feasibility of Quantifying Apoptosis and Bcl-2 Expression in Circulating Tumor Cells (CTCs) in Women Undergoing Treatment for Metastatic Breast Cancer
We are trying to develop better ways to detect when cancer therapies are working.
Inclusion Criteria:
1.Females at least 18 years of age 2 Diagnosis of metastatic breast cancer 3.ECOG Score of
0-2 4.Treating oncologist has decided to initiate any new systemic therapy with emphasis
on recruiting patients commencing a taxane-based regimen. Taxine-based therapy may be
docetaxel or paclitaxel, and it can be given on any schedule,including weekly or every 3
weeks. Other treatment can include non-taxane chemotherapy or trastuzumab-with or without
other therapy.
5.Patient is willing to return for one or more additional ~18 mL blood draw (s) at 24-48-,
and /or 72 hours and ~3-4 weeks after the initiation of therapy.At a minimum, patients
must donate blood at baseline, one intermediate interval (24, 48, 72 hr) and at ~3-4 weeks
6.Signed Informed Consent Form
Exclusion Criteria:
Patient is unable and unwilling to provide a blood specimen at a minimum of one of the
intermediate blood draw time points at 24, 48, or 72 hours -
We found this trial at
1
site
Click here to add this to my saved trials